Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event
affecting patients with cancer and patients with osteoporosis who have been treated with …

It is well established that alterations in phosphate metabolism have a profound effect on
hard and soft tissues of the oral cavity. The present-day clinical form of osteonecrosis of the …

Abstract The bisphosphonates ((HO) 2 P (O) CR 1 R 2 P (O)(OH) 2, BPs) were first shown to
inhibit bone resorption in the 1960s, but it was not until 30 years later that a detailed …

Natural polymers have been particularly appealing for constructing hemostatic
materials/devices, but it is still desirable to develop new natural polymer-based biomaterials …

Since the initial description of medication‐related osteonecrosis of the jaw (MRONJ) almost
two decades ago, the potential pathophysiology and risk factors have been elaborated on in …

Invasive dental treatment such as tooth extraction following treatment with strong anti-bone
resorptive agents, including bisphosphonates and denosumab, reportedly promotes …

Bisphosphonates (BPs) are characterized by their ability to bind strongly to bone mineral
and inhibit bone resorption. However, BPs exert a wide range of pharmacological activities …

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) presents as a morbid jawbone
lesion in patients exposed to a nitrogen-containing bisphosphonate (N-BP). Although it is …

Objective To assess the outcomes of several rodent animal models for studying tooth
extraction-related medication-related osteonecrosis of the jaw (MRONJ). Design After a …

Medication-related osteonecrosis of the jaw (MRONJ) is primarily associated with
administering antiresorptive or antiangiogenic drugs. Despite significant research on …